A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: AC682
Sponsor: Accutar Biotechnology Inc